PubRank

Alessandra Fabi

Author PubWeight™ 47.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005 1.87
2 Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008 1.61
3 Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2010 1.47
4 HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007 1.25
5 Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005 1.15
6 Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 2003 1.14
7 HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2008 1.13
8 The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res 2013 1.11
9 Testis metastasis as an initial manifestation of an occult gastrointestinal cancer. Anticancer Res 2004 1.09
10 Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One 2008 1.08
11 A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008 1.06
12 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 2010 0.97
13 Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011 0.96
14 Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 2012 0.93
15 Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 2003 0.93
16 Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 2010 0.93
17 An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res 2013 0.91
18 Supportive care in neurooncology. Curr Opin Oncol 2010 0.90
19 Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 2009 0.89
20 Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. J Clin Oncol 2010 0.88
21 Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007 0.86
22 Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients. J Neurooncol 2008 0.85
23 Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007 0.85
24 Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J Neurooncol 2013 0.84
25 Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006 0.84
26 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer 2013 0.84
27 The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009 0.83
28 Zoledronic acid and angiogenesis. Clin Cancer Res 2007 0.83
29 Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases. J Exp Clin Cancer Res 2009 0.83
30 Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci 2009 0.82
31 Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. Anticancer Res 2008 0.81
32 Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006 0.81
33 Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 2003 0.81
34 Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J 2009 0.80
35 Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disord 2012 0.78
36 Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile? J Clin Oncol 2011 0.78
37 Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006 0.78
38 Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother Pharmacol 2010 0.77
39 Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients. Cancer Invest 2004 0.77
40 Weight of epilepsy in brain tumor patients. J Neurooncol 2014 0.77
41 Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol 2008 0.77
42 New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005 0.77
43 Perfusion Computed Tomography (PCT) adopting different perfusion metrics: recurrence of brain metastasis or radiation necrosis? Eur J Radiol 2011 0.77
44 Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev 2006 0.76
45 Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer. Oncologist 2006 0.76
46 Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality? J Clin Oncol 2005 0.76
47 Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis. Anticancer Res 2007 0.75
48 HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? J Clin Oncol 2004 0.75
49 What is the biological significance of circulating blood levels of metalloproteinases? Clin Cancer Res 2006 0.75
50 Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 2002 0.75
51 Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One 2015 0.75
52 Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2005 0.75
53 Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer. Oncologist 2006 0.75
54 Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? J Steroid Biochem Mol Biol 2003 0.75
55 Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: a case report and review of literature. Clin Neurol Neurosurg 2012 0.75
56 Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer? Breast 2005 0.75
57 Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial. Tumori 2014 0.75
58 Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. Bone 2007 0.75
59 Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. Thromb Res 2006 0.75
60 Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study. Clin Neuropharmacol 2017 0.75
61 Alfa-epoietin and anaemia in gynaecological cancer. Anticancer Res 2004 0.75
62 Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. Anticancer Res 2013 0.75
63 Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert Opin Investig Drugs 2007 0.75
64 Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res 2005 0.75
65 Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study. Cancer Nurs 2016 0.75